Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 9/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PTAFR | P25105 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591432 | 0.87 | KCNA5 (0.42) | KCNA5CYP11B1CYP11B2KCNJ5KCNJ3 | |
| SCHEMBL21592282 | 0.80 | CYP11B1 (0.40) | KCNA5CYP11B1CYP11B2KCNJ5KCNJ3 | |
| SCHEMBL21591506 | 0.79 | HDAC3 (0.40) | KCNA5CYP11B1CYP11B2KCNJ5KCNJ3 | |
| SCHEMBL21591463 | 0.77 | CYP11B1 (0.54) | KCNA5CYP11B1CYP11B2KCNJ5KCNJ3 | |
| SCHEMBL21591442 | 0.76 | KMT2A (0.35) | KCNA5CYP11B1CYP11B2ALDH1A1KDM4E | |
| SCHEMBL21592281 | 0.75 | KMT2A (0.39) | KCNA5CYP11B1CYP11B2ALDH1A1NPSR1 | |
| SCHEMBL21592278 | 0.70 | POLB (0.38) | KCNA5CYP11B1CYP11B2KCNJ5KCNJ3 | |
| SCHEMBL21591430 | 0.69 | CYP11B1 (0.64) | CYP11B1CYP11B2ALDH1A1POLB | |
| SCHEMBL21591440 | 0.69 | CYP11B1 (0.60) | CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL31361799 | 0.69 | ACHE (0.33) | KCNA5CYP11B1CYP11B2ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | claimed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | claimed |
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | KCNA5 2592/4885CYP11B1 43/4885CYP11B2 50/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | KCNA5 2592/4885CYP11B1 43/4885CYP11B2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.